Literature DB >> 6107563

Prostacyclin therapy of thrombotic thrombocytopenic purpura.

G T Budd, R M Bukowski, F V Lucas, A E Cato, D M Cocchetto.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6107563     DOI: 10.1016/s0140-6736(80)92071-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  9 in total

Review 1.  Nobel lecture, 8th December 1982. Adventures and excursions in bioassay: the stepping stones to prostacyclin.

Authors:  J R Vane
Journal:  Br J Pharmacol       Date:  1983-08       Impact factor: 8.739

Review 2.  Nobel lecture. Adventures and excursions in bioassay--the stepping stones to prostacyclin.

Authors:  J R Vane
Journal:  Postgrad Med J       Date:  1983-12       Impact factor: 2.401

Review 3.  Prostaglandins and the cardiovascular system.

Authors:  J R Vane
Journal:  Br Heart J       Date:  1983-05

4.  Prostacyclin infusion in haemolytic-uraemic syndrome of children.

Authors:  T J Beattie; A V Murphy; M L Willoughby; J J Belch
Journal:  Br Med J (Clin Res Ed)       Date:  1981-08-15

Review 5.  Eighth Gaddum Memorial Lecture. University of London Institute of Education, December 1980. Biological importance of prostacyclin.

Authors:  S Moncada
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

6.  Platelet factor 4 and the response to plasma exchange in the treatment of thrombotic thrombocytopenic purpura.

Authors:  G Wiedemann; I Kantner; M Schenke; E Schulz; T Wagner
Journal:  Klin Wochenschr       Date:  1989-05-15

7.  Side effects occurring during administration of epoprostenol (prostacyclin, PGI2), in man.

Authors:  H Pickles; J O'Grady
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

8.  [Thrombotic thrombocytopenic purpura].

Authors:  C Aul; R E Scharf; T Königshausen; W Schneider
Journal:  Klin Wochenschr       Date:  1985-02-04

9.  Prostacyclin.

Authors:  J R Vane
Journal:  J R Soc Med       Date:  1983-04       Impact factor: 18.000

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.